Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia

Is therapeutic response predicted by Rome III subgroups?

Yao Chun Hsu, Jyh Ming Liou, Tzeng Huey Yang, Wei Lun Hsu, Hwai Jeng Lin, Huei Tang Wu, Jaw Town Lin, Hsiu Po Wang, Ming Shiang Wu

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: The comparative effectiveness of proton pump inhibitor versus prokinetic therapy in relieving the symptoms of patients with functional dyspepsia remains unknown. Whether the Rome III subgroups predict therapeutic response has not been investigated. Methods: This was an open-label, parallel randomized controlled trial. A total of 329 adult outpatients fulfilling the Rome III criteria for functional dyspepsia were randomly allocated to receive either lansoprazole 30 mg once daily (n = 166) or mosapride 5 mg thrice daily (n = 163) for 2 weeks. Enrolled patients were evaluated with the validated Hong Kong Index questionnaire for symptom severity at baseline and at the end of the trial. The primary outcome was symptom relief as defined by the Hong Kong Index, and the secondary outcome was decrease of symptom scores. Post-hoc multivariate logistic regression analysis was conducted to identify independent predictors for therapeutic response. Results: After 2-week therapy, 50.6% (84/166) and 47.85% (78/163) of the patients treated with lansoprazole and mosapride, respectively, achieved significant symptom relief (odds ratio 1.12, 95% confidence interval 0.72-1.72, p = 0.62). Differences in decreases of symptom scores between lansoprazole and mosapride receivers were also insignificant (-0.08, 95% confidence interval -1.25 to 1.09, p = 0.89). Therapeutic responses to either pharmacotherapy did not differ in the subgroup of patients fulfilling the criteria for epigastric pain syndrome (n = 256) or in those fulfilling the criteria for postprandial distress syndrome (n = 161). Multivariate logistic regression confirmed that the treatment allocation and Rome III subgroup were unrelated to treatment outcome. Conclusions: The effectiveness of proton pump inhibitor therapy and that of prokinetic therapy in functional dyspepsia are not different, and cannot be predicted by Rome III subgroups.

Original languageEnglish
Pages (from-to)183-190
Number of pages8
JournalJournal of Gastroenterology
Volume46
Issue number2
DOIs
Publication statusPublished - Feb 2011
Externally publishedYes

Fingerprint

Proton Pump Inhibitors
Dyspepsia
Lansoprazole
Hong Kong
Therapeutics
Logistic Models
Confidence Intervals
Outpatients
Randomized Controlled Trials
Odds Ratio
Regression Analysis
Drug Therapy
Pain

Keywords

  • Epigastric pain syndrome
  • Functional dyspepsia
  • Lansoprazole
  • Mosapride
  • Postprandial distress syndrome

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia : Is therapeutic response predicted by Rome III subgroups? / Hsu, Yao Chun; Liou, Jyh Ming; Yang, Tzeng Huey; Hsu, Wei Lun; Lin, Hwai Jeng; Wu, Huei Tang; Lin, Jaw Town; Wang, Hsiu Po; Wu, Ming Shiang.

In: Journal of Gastroenterology, Vol. 46, No. 2, 02.2011, p. 183-190.

Research output: Contribution to journalArticle

Hsu, Yao Chun ; Liou, Jyh Ming ; Yang, Tzeng Huey ; Hsu, Wei Lun ; Lin, Hwai Jeng ; Wu, Huei Tang ; Lin, Jaw Town ; Wang, Hsiu Po ; Wu, Ming Shiang. / Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia : Is therapeutic response predicted by Rome III subgroups?. In: Journal of Gastroenterology. 2011 ; Vol. 46, No. 2. pp. 183-190.
@article{8b0dcb403a76490289a04bdb138a07cf,
title = "Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: Is therapeutic response predicted by Rome III subgroups?",
abstract = "Background: The comparative effectiveness of proton pump inhibitor versus prokinetic therapy in relieving the symptoms of patients with functional dyspepsia remains unknown. Whether the Rome III subgroups predict therapeutic response has not been investigated. Methods: This was an open-label, parallel randomized controlled trial. A total of 329 adult outpatients fulfilling the Rome III criteria for functional dyspepsia were randomly allocated to receive either lansoprazole 30 mg once daily (n = 166) or mosapride 5 mg thrice daily (n = 163) for 2 weeks. Enrolled patients were evaluated with the validated Hong Kong Index questionnaire for symptom severity at baseline and at the end of the trial. The primary outcome was symptom relief as defined by the Hong Kong Index, and the secondary outcome was decrease of symptom scores. Post-hoc multivariate logistic regression analysis was conducted to identify independent predictors for therapeutic response. Results: After 2-week therapy, 50.6{\%} (84/166) and 47.85{\%} (78/163) of the patients treated with lansoprazole and mosapride, respectively, achieved significant symptom relief (odds ratio 1.12, 95{\%} confidence interval 0.72-1.72, p = 0.62). Differences in decreases of symptom scores between lansoprazole and mosapride receivers were also insignificant (-0.08, 95{\%} confidence interval -1.25 to 1.09, p = 0.89). Therapeutic responses to either pharmacotherapy did not differ in the subgroup of patients fulfilling the criteria for epigastric pain syndrome (n = 256) or in those fulfilling the criteria for postprandial distress syndrome (n = 161). Multivariate logistic regression confirmed that the treatment allocation and Rome III subgroup were unrelated to treatment outcome. Conclusions: The effectiveness of proton pump inhibitor therapy and that of prokinetic therapy in functional dyspepsia are not different, and cannot be predicted by Rome III subgroups.",
keywords = "Epigastric pain syndrome, Functional dyspepsia, Lansoprazole, Mosapride, Postprandial distress syndrome",
author = "Hsu, {Yao Chun} and Liou, {Jyh Ming} and Yang, {Tzeng Huey} and Hsu, {Wei Lun} and Lin, {Hwai Jeng} and Wu, {Huei Tang} and Lin, {Jaw Town} and Wang, {Hsiu Po} and Wu, {Ming Shiang}",
year = "2011",
month = "2",
doi = "10.1007/s00535-010-0334-1",
language = "English",
volume = "46",
pages = "183--190",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia

T2 - Is therapeutic response predicted by Rome III subgroups?

AU - Hsu, Yao Chun

AU - Liou, Jyh Ming

AU - Yang, Tzeng Huey

AU - Hsu, Wei Lun

AU - Lin, Hwai Jeng

AU - Wu, Huei Tang

AU - Lin, Jaw Town

AU - Wang, Hsiu Po

AU - Wu, Ming Shiang

PY - 2011/2

Y1 - 2011/2

N2 - Background: The comparative effectiveness of proton pump inhibitor versus prokinetic therapy in relieving the symptoms of patients with functional dyspepsia remains unknown. Whether the Rome III subgroups predict therapeutic response has not been investigated. Methods: This was an open-label, parallel randomized controlled trial. A total of 329 adult outpatients fulfilling the Rome III criteria for functional dyspepsia were randomly allocated to receive either lansoprazole 30 mg once daily (n = 166) or mosapride 5 mg thrice daily (n = 163) for 2 weeks. Enrolled patients were evaluated with the validated Hong Kong Index questionnaire for symptom severity at baseline and at the end of the trial. The primary outcome was symptom relief as defined by the Hong Kong Index, and the secondary outcome was decrease of symptom scores. Post-hoc multivariate logistic regression analysis was conducted to identify independent predictors for therapeutic response. Results: After 2-week therapy, 50.6% (84/166) and 47.85% (78/163) of the patients treated with lansoprazole and mosapride, respectively, achieved significant symptom relief (odds ratio 1.12, 95% confidence interval 0.72-1.72, p = 0.62). Differences in decreases of symptom scores between lansoprazole and mosapride receivers were also insignificant (-0.08, 95% confidence interval -1.25 to 1.09, p = 0.89). Therapeutic responses to either pharmacotherapy did not differ in the subgroup of patients fulfilling the criteria for epigastric pain syndrome (n = 256) or in those fulfilling the criteria for postprandial distress syndrome (n = 161). Multivariate logistic regression confirmed that the treatment allocation and Rome III subgroup were unrelated to treatment outcome. Conclusions: The effectiveness of proton pump inhibitor therapy and that of prokinetic therapy in functional dyspepsia are not different, and cannot be predicted by Rome III subgroups.

AB - Background: The comparative effectiveness of proton pump inhibitor versus prokinetic therapy in relieving the symptoms of patients with functional dyspepsia remains unknown. Whether the Rome III subgroups predict therapeutic response has not been investigated. Methods: This was an open-label, parallel randomized controlled trial. A total of 329 adult outpatients fulfilling the Rome III criteria for functional dyspepsia were randomly allocated to receive either lansoprazole 30 mg once daily (n = 166) or mosapride 5 mg thrice daily (n = 163) for 2 weeks. Enrolled patients were evaluated with the validated Hong Kong Index questionnaire for symptom severity at baseline and at the end of the trial. The primary outcome was symptom relief as defined by the Hong Kong Index, and the secondary outcome was decrease of symptom scores. Post-hoc multivariate logistic regression analysis was conducted to identify independent predictors for therapeutic response. Results: After 2-week therapy, 50.6% (84/166) and 47.85% (78/163) of the patients treated with lansoprazole and mosapride, respectively, achieved significant symptom relief (odds ratio 1.12, 95% confidence interval 0.72-1.72, p = 0.62). Differences in decreases of symptom scores between lansoprazole and mosapride receivers were also insignificant (-0.08, 95% confidence interval -1.25 to 1.09, p = 0.89). Therapeutic responses to either pharmacotherapy did not differ in the subgroup of patients fulfilling the criteria for epigastric pain syndrome (n = 256) or in those fulfilling the criteria for postprandial distress syndrome (n = 161). Multivariate logistic regression confirmed that the treatment allocation and Rome III subgroup were unrelated to treatment outcome. Conclusions: The effectiveness of proton pump inhibitor therapy and that of prokinetic therapy in functional dyspepsia are not different, and cannot be predicted by Rome III subgroups.

KW - Epigastric pain syndrome

KW - Functional dyspepsia

KW - Lansoprazole

KW - Mosapride

KW - Postprandial distress syndrome

UR - http://www.scopus.com/inward/record.url?scp=79954442464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954442464&partnerID=8YFLogxK

U2 - 10.1007/s00535-010-0334-1

DO - 10.1007/s00535-010-0334-1

M3 - Article

VL - 46

SP - 183

EP - 190

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 2

ER -